Stockreport

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies [Yahoo! Finance]

Lyell Immunopharma, Inc.  (LYEL) 
PDF Data from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3 rd line CAR-naïve setting to be presented [Read more]